Loading…

CCL2, CCR2 Gene Variants and CCL2, CCR2 Serum Levels Association with Age-Related Macular Degeneration

Background: Age-related macular degeneration (AMD) is the most common cause of progressive and irreversible blindness in developed countries. Although the pathogenesis is not fully understood, AMD is a multifactorial pathology with an accumulation of inflammatory components and macrophages and a str...

Full description

Saved in:
Bibliographic Details
Published in:Life (Basel, Switzerland) Switzerland), 2022-07, Vol.12 (7), p.1038
Main Authors: Gudauskiene, Gaile, Vilkeviciute, Alvita, Gedvilaite, Greta, Liutkeviciene, Rasa, Zaliuniene, Dalia
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c412t-93fb3df1806366176e1d57daea55cf310f3a472a868072701985ea0ec91a273b3
container_end_page
container_issue 7
container_start_page 1038
container_title Life (Basel, Switzerland)
container_volume 12
creator Gudauskiene, Gaile
Vilkeviciute, Alvita
Gedvilaite, Greta
Liutkeviciene, Rasa
Zaliuniene, Dalia
description Background: Age-related macular degeneration (AMD) is the most common cause of progressive and irreversible blindness in developed countries. Although the pathogenesis is not fully understood, AMD is a multifactorial pathology with an accumulation of inflammatory components and macrophages and a strong genetic predisposition. Our purpose was to investigate the association between early AMD and CCL2 (rs1024611, rs4586, rs2857656) and CCR2 (rs1799865) single nucleotide polymorphisms (SNPs) and CCL2, CCR2 serum levels in a Lithuanian population. Methods: The study included 310 patients with early AMD and 384 healthy subjects. Genotyping of CCL2 rs1024611, rs4586, rs2857656, and CCR2 rs1799865 was performed using a real-time polymerase chain reaction method, while CCL2 and CCR2 chemokines serum concentrations were analyzed using an enzyme-linked immunosorbent assay. Results: We found that the G allele at CCL2 rs1024611 was more prevalent in the early AMD group than in controls (29.2% vs. 24.1%, p = 0.032). Similarly, the C allele in CCL2 rs2857656 is more common in the early AMD group than in controls (29.2% vs. 24.2%, p = 0.037). Binomial logistic regression revealed that each G allele in rs1024611 was associated with 1.3-fold increased odds of developing early AMD under the additive model (OR = 1.322; 95% CI: 1.032–1.697, p = 0.027) as was each C allele in rs2857656 under the additive model (OR = 1.314; 95% CI: 1.025–1.684, p = 0.031). Haplotype analysis revealed that the C-A-G haplotype of CCL2 SNPs was associated with 35% decreased odds of early AMD development. Further analysis showed elevated CCL2 serum levels in the group with early AMD compared to controls (median (IQR): 1181.6 (522.6) pg/mL vs. 879.9 (494.4) pg/mL, p = 0.013); however, there were no differences between CCR2 serum levels within groups. Conclusions: We found the associations between minor alleles at CCL2 rs1024611 and rs2857656, elevated CCL2 serum levels, and early AMD development.
doi_str_mv 10.3390/life12071038
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_1db4c416d0cd4a5198315dc5e5e58a9d</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_1db4c416d0cd4a5198315dc5e5e58a9d</doaj_id><sourcerecordid>2693974898</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-93fb3df1806366176e1d57daea55cf310f3a472a868072701985ea0ec91a273b3</originalsourceid><addsrcrecordid>eNpdkktvEzEQgC0EolXojR9giQuHBvxYvy5I0RZKpSCk8rhaE3s23WizLvZuEf8et6lQyvgwI8-nzyNrCHnN2TspHXs_9B1ywQxn0j4jp7VSS26Ee35Un5CzUnashlZc2-YlOZHKWsuFPiVd267FOW3ba0EvcUT6E3IP41QojJEeNb9hnvd0jXc4FLoqJYUepj6N9Hc_3dDVFpfXOMCEkX6BMA-Q6QVuqzA_UK_Iiw6GgmePeUF-fPr4vf28XH-9vGpX62VouJiWTnYbGTtumZZac6ORR2UiICgVOslZJ6ExAqy2zAjDuLMKgWFwHISRG7kgVwdvTLDzt7nfQ_7jE_T-4SLlrYc89WFAz-Omqa_qyEJsQFWV5CoGhfVYcLG6Phxct_NmjzHgOGUYnkifdsb-xm_TnXdSiEaaKnj7KMjp14xl8vu-BBwGGDHNxQvtlLDOGFnRN_-huzTnsX7VPSWdaWydb0HOD1TIqZSM3b9hOPP3--CP90H-BVEdo50</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2693974898</pqid></control><display><type>article</type><title>CCL2, CCR2 Gene Variants and CCL2, CCR2 Serum Levels Association with Age-Related Macular Degeneration</title><source>PubMed (Medline)</source><source>Publicly Available Content Database</source><creator>Gudauskiene, Gaile ; Vilkeviciute, Alvita ; Gedvilaite, Greta ; Liutkeviciene, Rasa ; Zaliuniene, Dalia</creator><creatorcontrib>Gudauskiene, Gaile ; Vilkeviciute, Alvita ; Gedvilaite, Greta ; Liutkeviciene, Rasa ; Zaliuniene, Dalia</creatorcontrib><description>Background: Age-related macular degeneration (AMD) is the most common cause of progressive and irreversible blindness in developed countries. Although the pathogenesis is not fully understood, AMD is a multifactorial pathology with an accumulation of inflammatory components and macrophages and a strong genetic predisposition. Our purpose was to investigate the association between early AMD and CCL2 (rs1024611, rs4586, rs2857656) and CCR2 (rs1799865) single nucleotide polymorphisms (SNPs) and CCL2, CCR2 serum levels in a Lithuanian population. Methods: The study included 310 patients with early AMD and 384 healthy subjects. Genotyping of CCL2 rs1024611, rs4586, rs2857656, and CCR2 rs1799865 was performed using a real-time polymerase chain reaction method, while CCL2 and CCR2 chemokines serum concentrations were analyzed using an enzyme-linked immunosorbent assay. Results: We found that the G allele at CCL2 rs1024611 was more prevalent in the early AMD group than in controls (29.2% vs. 24.1%, p = 0.032). Similarly, the C allele in CCL2 rs2857656 is more common in the early AMD group than in controls (29.2% vs. 24.2%, p = 0.037). Binomial logistic regression revealed that each G allele in rs1024611 was associated with 1.3-fold increased odds of developing early AMD under the additive model (OR = 1.322; 95% CI: 1.032–1.697, p = 0.027) as was each C allele in rs2857656 under the additive model (OR = 1.314; 95% CI: 1.025–1.684, p = 0.031). Haplotype analysis revealed that the C-A-G haplotype of CCL2 SNPs was associated with 35% decreased odds of early AMD development. Further analysis showed elevated CCL2 serum levels in the group with early AMD compared to controls (median (IQR): 1181.6 (522.6) pg/mL vs. 879.9 (494.4) pg/mL, p = 0.013); however, there were no differences between CCR2 serum levels within groups. Conclusions: We found the associations between minor alleles at CCL2 rs1024611 and rs2857656, elevated CCL2 serum levels, and early AMD development.</description><identifier>ISSN: 2075-1729</identifier><identifier>EISSN: 2075-1729</identifier><identifier>DOI: 10.3390/life12071038</identifier><identifier>PMID: 35888126</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Age ; Age related diseases ; Alleles ; AMD ; Binding sites ; Cardiovascular disease ; CCL2 (rs1024611, rs4586, rs2857656) ; CCL2 and CCR2 serum level ; CCR2 protein ; CCR2 rs1799865 ; Chemokines ; Deoxyribonucleic acid ; Developed countries ; DNA ; Enzyme-linked immunosorbent assay ; Eye diseases ; Genes ; Genotyping ; Haplotypes ; Inflammation ; Laboratories ; Macrophages ; Macular degeneration ; Minority &amp; ethnic groups ; Monocyte chemoattractant protein 1 ; Neurosciences ; Nucleotides ; Ophthalmology ; Oxidative stress ; Pathogenesis ; Polymerase chain reaction ; Population studies ; Serum levels ; Single-nucleotide polymorphism ; Statistical analysis</subject><ispartof>Life (Basel, Switzerland), 2022-07, Vol.12 (7), p.1038</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c412t-93fb3df1806366176e1d57daea55cf310f3a472a868072701985ea0ec91a273b3</cites><orcidid>0000-0001-7469-8825 ; 0000-0002-0427-5568</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2693974898/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2693974898?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids></links><search><creatorcontrib>Gudauskiene, Gaile</creatorcontrib><creatorcontrib>Vilkeviciute, Alvita</creatorcontrib><creatorcontrib>Gedvilaite, Greta</creatorcontrib><creatorcontrib>Liutkeviciene, Rasa</creatorcontrib><creatorcontrib>Zaliuniene, Dalia</creatorcontrib><title>CCL2, CCR2 Gene Variants and CCL2, CCR2 Serum Levels Association with Age-Related Macular Degeneration</title><title>Life (Basel, Switzerland)</title><description>Background: Age-related macular degeneration (AMD) is the most common cause of progressive and irreversible blindness in developed countries. Although the pathogenesis is not fully understood, AMD is a multifactorial pathology with an accumulation of inflammatory components and macrophages and a strong genetic predisposition. Our purpose was to investigate the association between early AMD and CCL2 (rs1024611, rs4586, rs2857656) and CCR2 (rs1799865) single nucleotide polymorphisms (SNPs) and CCL2, CCR2 serum levels in a Lithuanian population. Methods: The study included 310 patients with early AMD and 384 healthy subjects. Genotyping of CCL2 rs1024611, rs4586, rs2857656, and CCR2 rs1799865 was performed using a real-time polymerase chain reaction method, while CCL2 and CCR2 chemokines serum concentrations were analyzed using an enzyme-linked immunosorbent assay. Results: We found that the G allele at CCL2 rs1024611 was more prevalent in the early AMD group than in controls (29.2% vs. 24.1%, p = 0.032). Similarly, the C allele in CCL2 rs2857656 is more common in the early AMD group than in controls (29.2% vs. 24.2%, p = 0.037). Binomial logistic regression revealed that each G allele in rs1024611 was associated with 1.3-fold increased odds of developing early AMD under the additive model (OR = 1.322; 95% CI: 1.032–1.697, p = 0.027) as was each C allele in rs2857656 under the additive model (OR = 1.314; 95% CI: 1.025–1.684, p = 0.031). Haplotype analysis revealed that the C-A-G haplotype of CCL2 SNPs was associated with 35% decreased odds of early AMD development. Further analysis showed elevated CCL2 serum levels in the group with early AMD compared to controls (median (IQR): 1181.6 (522.6) pg/mL vs. 879.9 (494.4) pg/mL, p = 0.013); however, there were no differences between CCR2 serum levels within groups. Conclusions: We found the associations between minor alleles at CCL2 rs1024611 and rs2857656, elevated CCL2 serum levels, and early AMD development.</description><subject>Age</subject><subject>Age related diseases</subject><subject>Alleles</subject><subject>AMD</subject><subject>Binding sites</subject><subject>Cardiovascular disease</subject><subject>CCL2 (rs1024611, rs4586, rs2857656)</subject><subject>CCL2 and CCR2 serum level</subject><subject>CCR2 protein</subject><subject>CCR2 rs1799865</subject><subject>Chemokines</subject><subject>Deoxyribonucleic acid</subject><subject>Developed countries</subject><subject>DNA</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Eye diseases</subject><subject>Genes</subject><subject>Genotyping</subject><subject>Haplotypes</subject><subject>Inflammation</subject><subject>Laboratories</subject><subject>Macrophages</subject><subject>Macular degeneration</subject><subject>Minority &amp; ethnic groups</subject><subject>Monocyte chemoattractant protein 1</subject><subject>Neurosciences</subject><subject>Nucleotides</subject><subject>Ophthalmology</subject><subject>Oxidative stress</subject><subject>Pathogenesis</subject><subject>Polymerase chain reaction</subject><subject>Population studies</subject><subject>Serum levels</subject><subject>Single-nucleotide polymorphism</subject><subject>Statistical analysis</subject><issn>2075-1729</issn><issn>2075-1729</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkktvEzEQgC0EolXojR9giQuHBvxYvy5I0RZKpSCk8rhaE3s23WizLvZuEf8et6lQyvgwI8-nzyNrCHnN2TspHXs_9B1ywQxn0j4jp7VSS26Ee35Un5CzUnashlZc2-YlOZHKWsuFPiVd267FOW3ba0EvcUT6E3IP41QojJEeNb9hnvd0jXc4FLoqJYUepj6N9Hc_3dDVFpfXOMCEkX6BMA-Q6QVuqzA_UK_Iiw6GgmePeUF-fPr4vf28XH-9vGpX62VouJiWTnYbGTtumZZac6ORR2UiICgVOslZJ6ExAqy2zAjDuLMKgWFwHISRG7kgVwdvTLDzt7nfQ_7jE_T-4SLlrYc89WFAz-Omqa_qyEJsQFWV5CoGhfVYcLG6Phxct_NmjzHgOGUYnkifdsb-xm_TnXdSiEaaKnj7KMjp14xl8vu-BBwGGDHNxQvtlLDOGFnRN_-huzTnsX7VPSWdaWydb0HOD1TIqZSM3b9hOPP3--CP90H-BVEdo50</recordid><startdate>20220712</startdate><enddate>20220712</enddate><creator>Gudauskiene, Gaile</creator><creator>Vilkeviciute, Alvita</creator><creator>Gedvilaite, Greta</creator><creator>Liutkeviciene, Rasa</creator><creator>Zaliuniene, Dalia</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>P64</scope><scope>PATMY</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7469-8825</orcidid><orcidid>https://orcid.org/0000-0002-0427-5568</orcidid></search><sort><creationdate>20220712</creationdate><title>CCL2, CCR2 Gene Variants and CCL2, CCR2 Serum Levels Association with Age-Related Macular Degeneration</title><author>Gudauskiene, Gaile ; Vilkeviciute, Alvita ; Gedvilaite, Greta ; Liutkeviciene, Rasa ; Zaliuniene, Dalia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-93fb3df1806366176e1d57daea55cf310f3a472a868072701985ea0ec91a273b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Age</topic><topic>Age related diseases</topic><topic>Alleles</topic><topic>AMD</topic><topic>Binding sites</topic><topic>Cardiovascular disease</topic><topic>CCL2 (rs1024611, rs4586, rs2857656)</topic><topic>CCL2 and CCR2 serum level</topic><topic>CCR2 protein</topic><topic>CCR2 rs1799865</topic><topic>Chemokines</topic><topic>Deoxyribonucleic acid</topic><topic>Developed countries</topic><topic>DNA</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Eye diseases</topic><topic>Genes</topic><topic>Genotyping</topic><topic>Haplotypes</topic><topic>Inflammation</topic><topic>Laboratories</topic><topic>Macrophages</topic><topic>Macular degeneration</topic><topic>Minority &amp; ethnic groups</topic><topic>Monocyte chemoattractant protein 1</topic><topic>Neurosciences</topic><topic>Nucleotides</topic><topic>Ophthalmology</topic><topic>Oxidative stress</topic><topic>Pathogenesis</topic><topic>Polymerase chain reaction</topic><topic>Population studies</topic><topic>Serum levels</topic><topic>Single-nucleotide polymorphism</topic><topic>Statistical analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gudauskiene, Gaile</creatorcontrib><creatorcontrib>Vilkeviciute, Alvita</creatorcontrib><creatorcontrib>Gedvilaite, Greta</creatorcontrib><creatorcontrib>Liutkeviciene, Rasa</creatorcontrib><creatorcontrib>Zaliuniene, Dalia</creatorcontrib><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Biological Science Journals</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Life (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gudauskiene, Gaile</au><au>Vilkeviciute, Alvita</au><au>Gedvilaite, Greta</au><au>Liutkeviciene, Rasa</au><au>Zaliuniene, Dalia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CCL2, CCR2 Gene Variants and CCL2, CCR2 Serum Levels Association with Age-Related Macular Degeneration</atitle><jtitle>Life (Basel, Switzerland)</jtitle><date>2022-07-12</date><risdate>2022</risdate><volume>12</volume><issue>7</issue><spage>1038</spage><pages>1038-</pages><issn>2075-1729</issn><eissn>2075-1729</eissn><abstract>Background: Age-related macular degeneration (AMD) is the most common cause of progressive and irreversible blindness in developed countries. Although the pathogenesis is not fully understood, AMD is a multifactorial pathology with an accumulation of inflammatory components and macrophages and a strong genetic predisposition. Our purpose was to investigate the association between early AMD and CCL2 (rs1024611, rs4586, rs2857656) and CCR2 (rs1799865) single nucleotide polymorphisms (SNPs) and CCL2, CCR2 serum levels in a Lithuanian population. Methods: The study included 310 patients with early AMD and 384 healthy subjects. Genotyping of CCL2 rs1024611, rs4586, rs2857656, and CCR2 rs1799865 was performed using a real-time polymerase chain reaction method, while CCL2 and CCR2 chemokines serum concentrations were analyzed using an enzyme-linked immunosorbent assay. Results: We found that the G allele at CCL2 rs1024611 was more prevalent in the early AMD group than in controls (29.2% vs. 24.1%, p = 0.032). Similarly, the C allele in CCL2 rs2857656 is more common in the early AMD group than in controls (29.2% vs. 24.2%, p = 0.037). Binomial logistic regression revealed that each G allele in rs1024611 was associated with 1.3-fold increased odds of developing early AMD under the additive model (OR = 1.322; 95% CI: 1.032–1.697, p = 0.027) as was each C allele in rs2857656 under the additive model (OR = 1.314; 95% CI: 1.025–1.684, p = 0.031). Haplotype analysis revealed that the C-A-G haplotype of CCL2 SNPs was associated with 35% decreased odds of early AMD development. Further analysis showed elevated CCL2 serum levels in the group with early AMD compared to controls (median (IQR): 1181.6 (522.6) pg/mL vs. 879.9 (494.4) pg/mL, p = 0.013); however, there were no differences between CCR2 serum levels within groups. Conclusions: We found the associations between minor alleles at CCL2 rs1024611 and rs2857656, elevated CCL2 serum levels, and early AMD development.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>35888126</pmid><doi>10.3390/life12071038</doi><orcidid>https://orcid.org/0000-0001-7469-8825</orcidid><orcidid>https://orcid.org/0000-0002-0427-5568</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2075-1729
ispartof Life (Basel, Switzerland), 2022-07, Vol.12 (7), p.1038
issn 2075-1729
2075-1729
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_1db4c416d0cd4a5198315dc5e5e58a9d
source PubMed (Medline); Publicly Available Content Database
subjects Age
Age related diseases
Alleles
AMD
Binding sites
Cardiovascular disease
CCL2 (rs1024611, rs4586, rs2857656)
CCL2 and CCR2 serum level
CCR2 protein
CCR2 rs1799865
Chemokines
Deoxyribonucleic acid
Developed countries
DNA
Enzyme-linked immunosorbent assay
Eye diseases
Genes
Genotyping
Haplotypes
Inflammation
Laboratories
Macrophages
Macular degeneration
Minority & ethnic groups
Monocyte chemoattractant protein 1
Neurosciences
Nucleotides
Ophthalmology
Oxidative stress
Pathogenesis
Polymerase chain reaction
Population studies
Serum levels
Single-nucleotide polymorphism
Statistical analysis
title CCL2, CCR2 Gene Variants and CCL2, CCR2 Serum Levels Association with Age-Related Macular Degeneration
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T08%3A16%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CCL2,%20CCR2%20Gene%20Variants%20and%20CCL2,%20CCR2%20Serum%20Levels%20Association%20with%20Age-Related%20Macular%20Degeneration&rft.jtitle=Life%20(Basel,%20Switzerland)&rft.au=Gudauskiene,%20Gaile&rft.date=2022-07-12&rft.volume=12&rft.issue=7&rft.spage=1038&rft.pages=1038-&rft.issn=2075-1729&rft.eissn=2075-1729&rft_id=info:doi/10.3390/life12071038&rft_dat=%3Cproquest_doaj_%3E2693974898%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c412t-93fb3df1806366176e1d57daea55cf310f3a472a868072701985ea0ec91a273b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2693974898&rft_id=info:pmid/35888126&rfr_iscdi=true